Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

class="prnews_span">-15,415-100,190-150,259-Janssen's share of pre-tax profits

50%50%50%50%Total Cost of collaboration (Janssen's 50% share as per the Agreement)

$
50,095
$
-
$
75,130
$
-
Pharmacyclics' 50% share of net product revenue less cost of goods sold

$
50,095
$
-
$
75,130
$
-
(3)The Company's total share of net costs under the Agreement did not exceed the $50 million annual cap provided for in the Agreement. As such, no Excess Amounts were recorded for the three and six months ended June 30, 2014. Regulatory UpdateOn July 28, 2014, the U.S. FDA granted IMBRUVICA full approval for the treatment of CLL patients who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naive (frontline) and previously treated del 17p CLL patients. This was the first full FDA approval for IMBRUVICA, and was granted only five and a half months after the original accelerated approval for patients with previously treated CLL, which was granted in February 2014. 

This full approval is based on data from the Phase III RESONATE study (PCYC-1112-CA), a randomized, multi-center, international head-to-head comparison of single-agent, orally-administered IMBRUVICA (ibrutinib) versus the intravenous, monoclonal an
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 20, 2015 ... announced the addition of the "Cardiometabolic Drug ... Afrezza,s discounted pricing is in line with ... critical to the product,s commercial appeal. However, contraindications, ... Afrezza from gaining a sizeable share of the ...
(Date:7/27/2015)... , July 27, 2015  Linear accelerators used ... machines, requiring not only adequate space for the ... their operation. Inherent to the size and complexity ... accelerator or the addition of a new vault ... operations risks interruption of patient treatment: with potential ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ) has ... Receptors Market: Global Industry Analysis, Size, Share, Growth, ... to their offering. The global ... assay type, therapeutic area, and geography. Based on ... into six major segments: cAMP assays, calcium level ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Phase II trial of a single,intraoperative administration of ... in the first 8 to 24 hours following,surgery, ... treatment.,The results of the multicenter, randomized, double-blind study ... Assembly in Anesthesiology in New York,City today, by ...
... Canada, Dec. 12 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... that identifies, develops and commercializes differentiated products for ... CIMYM BioSciences Inc. received a milestone payment from ... of the recent marketing approval of nimotuzumab in ...
Cached Medicine Technology:Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA) 2Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA) 3Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA) 4YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia 2YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia 3YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia 4
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges ... the foster care system to get into and complete college. , The “Bridging ... at an event today with partners from across the valley. , The initiative advisory ...
(Date:7/27/2015)... NY (PRWEB) , ... July 27, 2015 , ... ... tour. He will be performing for one additional night at each of his ... promo/coupon code DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... professional and in-depth research report. The report provides basic information such as ... etc. This report covers the global (US, Europe, Japan etc) industry analysis ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program ... to support its mission of reducing the number of deaths and injuries occurring from ... and their families. PursuitSAFETY works with the police to find better and safer ...
(Date:7/27/2015)... ... July 27, 2015 , ... Throughout its 20 year history, Doctors on ... working on a lien basis. As the personal injury and medical industries have ... chiropractors, to orthopedists, to pain management physicians, to psychologists and more. And while ...
Breaking Medicine News(10 mins):Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2
... students finds 20% took substances without approval , , MONDAY, ... non-medical use of frequently abused prescription drugs increases the ... study. , Researcher Sean Esteban McCabe asked 3,639 college ... non-prescribed use of four classes of prescription drugs -- ...
... clear association, but no such link for depression , , MONDAY, ... help bring on a stroke may have merit, British researchers ... groups according to how severe their stress is, someone in ... 40 percent increased risk of stroke than someone in the ...
... New York physicians,facing a potential surcharge in malpractice insurance ... an expected one thousand New,York physicians will be in ... Tuesday, March 4th where they will be addressed by ... Capitol steps by 12:30 p.m. to demand,justice and malpractice ...
... BIRMINGHAM, Ala., March 3 Emageon Inc.,(Nasdaq: ... technology,systems for hospitals, healthcare networks and imaging facilities ... will present at the,Raymond James 29th Annual Institutional ... Regency Grand Cypress, Orlando, Florida. Emageon will,present on ...
... ... Today 5,000 Nurses at 11 ... In an atmosphere that nurses,describe as attempted "intimidation" from Sutter ... authorize,their bargaining teams to strike the hospital chain for up to ...
... Rally Behind California Assembly Bills Protecting State,s,Elderly ... SACRAMENTO, Calif., March 3 California,seniors ... Senior Living have,teamed up with advocates and ... increases, and to address serious problems with ...
Cached Medicine News:Health News:Non-Medical Use of Prescriptions Linked to Drug Abuse Risk 2Health News:Stress Can Help Trigger Stroke 2Health News:Attention New York: Please Don't Get Sick on March 4th, Your Doctor Will be in Albany for Malpractice Insurance Reform 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 3Health News:'Atria Bills' Get Support From Assisted Living Residents, Family Members, Senior Groups 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
... 384 Well Plate Capability The Equalizer ... original Equalizerexpandable and equal tip spacing, choice of ... capabilities. In addition, this model allows you to ... loading and accessing many gels and for use ...
Medicine Products: